Boehringer Questions FDA Guidance on Child-Resistant Packaging Labels

Drug Industry Daily
Boehringer Ingelheim suggested the FDA draft guidance on child resistant packaging labeling, published in August, could confuse consumers who may not understand why only some drug products bear the CRP statement. Prescription drugs are often repackaged by dispensers or pharmacists, running the risk of the information never reaching the consumer, Boehringer said.

To View This Article:


Subscribe To Drug Industry Daily